Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...

A trial of Eli Lilly’s diabetes drug Mounjaro did not meet expectations for outperforming Trulicity in preventing heart ...

The trial enrolled more than 13,000 participants across 30 countries and lasted more than four and a half years. It was also the largest and longest study of tirzepatide --- the active ingredient in ...

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...